LY-293284 is a research chemical developed by the pharmaceutical company Eli Lilly and used for scientific studies. It acts as a potent and selective 5-HT1Areceptorfull agonist. It was derived through structural simplification of the ergoline based psychedelic LSD, but is far more selective for 5-HT1A with over 1000x selectivity over other serotonin receptor subtypes and other targets. It has anxiogenic effects in animal studies.
^Monte AP, Marona-Lewicka D, Lewis MM, Mailman RB, Wainscott DB, Nelson DL, Nichols DE (June 1998). "Substituted naphthofurans as hallucinogenic phenethylamine-ergoline hybrid molecules with unexpected muscarinic antagonist activity". Journal of Medicinal Chemistry. 41 (12): 2134–45. doi:10.1021/jm980076u. PMID9622555.
^Foreman MM, Fuller RW, Rasmussen K, Nelson DL, Calligaro DO, Zhang L, Barrett JE, Booher RN, Paget CJ, Flaugh ME (September 1994). "Pharmacological characterization of LY293284: A 5-HT1A receptor agonist with high potency and selectivity". The Journal of Pharmacology and Experimental Therapeutics. 270 (3): 1270–81. PMID7523657.
^Cao BJ, Rodgers RJ (October 1998). "Comparative effects of novel 5-HT1A receptor ligands, LY293284, LY315712 and LY297996, on plus-maze anxiety in mice". Psychopharmacology. 139 (3): 185–94. doi:10.1007/s002130050703. PMID9784072.